Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.36 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9051943 | 0.86 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL15623649 | 0.83 | TERT (0.42) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL15808516 | 0.83 | MEN1 (0.47) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL9214801 | 0.83 | TERT (0.42) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL21320459 | 0.82 | OPRD1 (0.35) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL1777471 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL13689604 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL17037425 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL17037424 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL26240124 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0922034-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS EAA ANTAGONISTS | GLAXO WELLCOME SPA (IT) | 2002-07-24 | — | — | EP | claimed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | US | disclosed |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| CN-109743875-B | Inhibitors of the MENIN-MLL interaction | 生命医药有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-7691879-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7622537-B2 | copolymerizing an amino acid mimetic monomer and hydrophobic acrylate monomers; amino acid mimetic monomers selected to mimic the side chain of the amino acids Asn or gln can be a (meth)acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide; biocompatible; coated stent | ABBOTT LABORATORIES (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-7488752-B2 | nor-seco himbacine derivatives; thrombosis, anticoagulants, anticancer agents; antiinflammatory agents; anticholesterol agents; cardiovascular disorders; antiarrhythmia agents; antiischemic agents; strokes; antiarthritic agents | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080221195-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080124450-A1 | copolymerizing an amino acid mimetic monomer and hydrophobic acrylate monomers; amino acid mimetic monomers selected to mimic the side chain of the amino acids Asn or gln can be a (meth)acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide; biocompatible; coated stent | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125514-A1 | Biocompatible polymers that include an amino acid mimetic monomer and one or more hydrophobic acrylate monomers, the amino acid mimetic monomers being selected to mimic the side chain of the amino acids asparagine or glutamine; mechanical strength, drug permeability | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2007038669-A9 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC | 2008-05-29 | — | — | WO | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000847-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | ALDH1A1 1992/4885LMNA 2845/4885MAPT 1108/4885 |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | ALDH1A1 4776/4885LMNA 2647/4885MAPT 2231/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | ALDH1A1 1992/4885LMNA 2845/4885MAPT 1108/4885 |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | ALDH1A1 3112/4885LMNA 62/4885MAPT 3851/4885 |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | ALDH1A1 1920/4885LMNA 204/4885MAPT 4063/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | ALDH1A1 4776/4885LMNA 2647/4885MAPT 2231/4885 |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | ALDH1A1 1360/4885LMNA 2839/4885MAPT 3898/4885 |
| US-20080221195-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | ALDH1A1 2416/4885LMNA 2918/4885MAPT 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.